Recombinant Human EPH Receptor A2, GST-tagged, Active

• Cat.No.: EPHA2-300H
• Product Overview: Recombinant human EPHA2 (561-end) was expressed by baculovirus inSf9 insect cellsusing an N-terminal GST tag. MW=72kDa.

Specification

• Cat. No.: EPHA2-300H
• Description: EPHA2 is a member of the ephrin receptor subfamily of protein-tyrosine kinases that bind the ephrin-A ligand and have diverse cellular function. EPHA2 has been shown to be an oncoprotein of importance in a range of cancers. EPHA2 is overexpressed in several human cancer types and promotes malignancy through a mechanism involving RhoA-dependent destabilization of adherens junctions. EPHA2 overexpression induces a FAK-dependent increase in MMP-2 expression and invasiveness and this process that can be reversed by ligation of EPHA2.
• Source: Sf9 insect cellsusing baculovirus.
• Sequence: 561-end.
• Applications: Kinase Assay, Western Blot.
• Storage And Stability: Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Gene Information

• Gene Name: EPHA2 EPH receptor A2 [ Homo sapiens ]
• Synonyms: EPHA2; EPH receptor A2; ECK; ARCC2; protein tyrosine kinase; soluble EPHA2 variant 1; soluble EPHA2 variant 1; epithelial cell receptor protein tyrosine kinase; ephrin receptor EphA2; EC 2.7.10.1
• Gene ID: 1969
• mRNA Refseq: NM_004431
• Protein Refseq: NP_004422
• MIM: 176946
• UniProt ID: P29317
• Chromosome Location: 1p36
• Pathway: Axon guidance
• Function: ATP binding; ephrin receptor activity; nucleotide binding; protein binding; receptor activity; transferase activity

Reviews

12/21/2022

The protein has low cytotoxicity.

02/03/2022

EPHA2 has good stability, and the test results of heat resistance, acid and alkali resistance and protease degradation resistance are good.

03/31/2021

Kinetic parameters such as enzymatic reaction rate and binding affinity were tested, and the protein performed well.

Q&As

What are the treatment strategies for EPHA2?

Therapeutic strategies for EPHA2 include inhibition of its expression, blocking its signal transduction pathway, and modulating its interaction with ligands. These strategies may involve the use of small molecule inhibitors, antibodies, or other types of therapeutics.

How does EPHA2 expression level relate to the occurrence and progression of the disease?

The expression level of EPHA2 is associated with the occurrence and progression of a variety of diseases. For example, in tumors such as lung, breast, and colorectal cancer, EPHA2 expression levels may be elevated and correlated with the degree of malignancy and poor prognosis of the tumor.

How does EPHA2 expression level relate to tumor prognosis?

In some tumors, EPHA2 expression levels are associated with poor prognosis in patients. For example, patients with lung cancer who express EPHA2 often have shorter survival. Therefore, the expression level of EPHA2 may be one of the indicators to predict tumor prognosis.

How can diseases be diagnosed by detecting EPHA2 expression levels?

Some diseases can be diagnosed by measuring EPHA2 expression levels, such as immunohistochemistry, western blotting, and real-time PCR.

Could EPHA2 be used as a target for the treatment of certain diseases?

Yes, EPHA2 can be used as a target for the treatment of certain diseases. For example, inhibition of EPHA2 expression can inhibit tumor growth and spread, so EPHA2 can serve as a potential therapeutic target. In addition, regulating the expression level of EPHA2 may also be helpful in the treatment of diseases such as the nervous system and cardiovascular system.

What is the role of EPHA2 in cancer metastasis?

EPHA2 can promote cancer metastasis and affect the spread and spread of cancer by regulating processes such as invasion and migration of tumor cells. Therefore, inhibition of EPHA2 expression or blocking its signal transduction pathway may have a potential therapeutic effect on inhibiting cancer metastasis.